Korean Chinese Japanese
  • Economy
  • Politics
  • Society
  • Securities
  • Real estate
  • Culture
  • Entertainment
  • Sports
  • Opinion
Korean Chinese Japanese
Economy Corporation Pharma & Bio
Society Politics IT·Science
Securities Real Estate Global
Opinion Entertainment Sports Culture
Video Auto in Golf in
PHARM EDAILY Market in TheBeLT
Pharma & Bio
Lifestyle

Kang Seong-min, CEO of PeopleBio, Inc.: “Full-Scale Launch of LDT and Diagnostic Kit Business in the U.S. … Revenue to Become Apparent Starting Next Year”

“Building on our designation as an innovative medical device by the U.S. Food and Drug Administration (FDA), we plan to establish a local subsidiary within this year. Next year, we will launch laborat…
  • 2026-09-19 08:07:02
  • YU JIN-HEE
Lifestyle

Orum Therapeutics, Inc. Reeling from BMS Technology Return… Sole Clinical Pipeline Disappears [Bio Spotlight]

On the 17th, stock prices in the biotech sector saw mixed results due to business restructuring and technology development issues at major companies. #Orum Therapeutics, Inc. plummeted by over 33% in …
  • 2026-09-19 07:42:09
  • KIM JI-WAN
Technology

Orum Loses Its Only Clinical Asset After BMS Withdraws[K-Bio Pulse]

Biotech stocks moved in sharply different directions on Sept. 17 as investors reacted to corporate restructuring and drug development updates.Orum Therapeutics plunged more than 33% in after-hours tra…
  • 2026-09-19 07:42:03
  • KIM JI-WAN
Technology

[Exclusive] Genomictree Inc. Receives NMPA Approval in China for Colorectal Cancer Diagnostic Kit

It has been confirmed that a product developed based on Genomictree Inc.(228760)’s early-stage colorectal cancer diagnostic technology has received marketing authorization from China’s National Medica…
  • 2026-09-18 17:42:02
  • KIM SAE-MI
Technology

Lotte Bio Faces Fears of Massive Depreciation at Songdo Plant... Desperately Needs to Secure Contracts by Year-End

Lotte Biologics has completed its Songdo Bio Campus Plant No. 1 after investing approximately 1.4 trillion won, but the company now finds itself in a position where it must bear massive fixed costs wi…
  • 2026-09-18 08:21:01
  • KIM SUNG-JIN
Lifestyle

Obesity and Diabetes Stocks Rally Sharply as Quratis and MFC Hit Daily Limit Gains [K-Bio Pulse]

As glucagon-like peptide-1 (GLP-1) therapies for obesity and diabetes establish themselves as a major trend in the global pharmaceutical and biotech sectors, strong buying momentum is driving interest…
  • 2026-09-18 08:12:03
  • YU JIN-HEE
Lifestyle

Obesity and Diabetes Treatment-Themed Stocks on the Rise… Quratis Inc. and MFC Co., Ltd. Hit Daily Price Limits [Bio Spotlight]

As glucagon-like peptide-1 (GLP-1) class obesity and diabetes treatments have established themselves as a major trend in the global pharmaceutical and biotech markets, strong buying momentum is gather…
  • 2026-09-18 08:12:02
  • YU JIN-HEE
Technology

“The Era of At-Home Cancer Treatment”… Why Herings and KGOG Are Developing a Gynecological Cancer Monitoring Platform

The focus of cancer treatment is shifting from hospital injection rooms to patients’ daily lives. This shift is driven by global pharmaceutical companies converting intravenous (IV) biologics—which us…
  • 2026-09-17 12:02:01
  • Kim Seung-kwon
Technology

1,500 Doctors Specializing in Clinical Trials in the U.S., 24 in South Korea… A Shortage of Medical Personnel

“While it was certain that the U.S. Food and Drug Administration (FDA) would respond within 30 days, I got the impression that the review process at the Ministry of Food and Drug Safety (MFDS) had a r…
  • 2026-09-17 11:56:02
  • NA EUN-KYUNG
Technology

“No Reform, No New Korean Drugs”… The MFDS’s IND Review in Light of the Kim Seung-won Incident

Kim Seung-won, nominee for Minister of Justice, delivers opening remarks during his confirmation hearing held on the 15th at the National Assembly’s Legislation and Judiciary Committee in Yeouido, Seo…
  • 2026-09-17 11:51:02
  • KIM SAE-MI
prev 21 22 23 24 25 26 27 28 29 30 next

PHARM EDAILY

Shorts

EDAILY
  • 92, Tongil-ro, Jung-gu, Seoul, Korea
  • +82 2 3772 0114
  • webmaster@edaily.co.kr

※ This article has been translated using AI technology for the convenience of readers.

EDAILY provides this translation on an “as is” basis and makes no warranties, express or implied, regarding its accuracy, reliability, completeness, merchantability, or fitness for a particular purpose.
Due to the limitations of machine translation, the translated content may differ from the original Korean article. In the event of any discrepancy, the original Korean version shall prevail.
EDAILY shall not be liable for any loss or damage arising from the use of, or reliance on, the translated content.

© 2026 Copyrights by edaily. All Rights Reserved.
Korea China Japan
English